Gilead Sciences

#GileadNews: Today, we received positive opinions from the #CHMP for our long-acting HIV prevention medication. If approved, it could be an important step toward expanding #HIV prevention options in Europe and beyond: gilead.inc/3ILympx

At #IAS2025, we invited advocates to share the impact of community involvement in the #HIV landscape. Hear how, together, we’re helping shape the future of research and taking steps to end the epidemic.

A powerful Sunday at the @aidswalksf! Gilead employees joined the nearly 40-year tradition, supporting community organizations and raising funds for #HIV care. We are deeply honored to partner as we work together to help end the HIV epidemic for everyone, everywhere.

Women are leading efforts to help end #HIV by driving research, raising awareness and advocating for better health for all. Hear more from #IAS2025 on the importance of their perspectives in innovation.

Progress demands more than a vision; it requires innovation built for impact. Our scientific focus addresses the most urgent unmet needs, as we strive to create a healthier world for all people by delivering more than 10 transformative medicines by 2030.

In the U.S., 85% of people believe #HIV stigma still exists. On #ZeroHIVStigmaDay, we recognize the resilience of individuals like Morris who navigate life with HIV and advocate for change. At Gilead, we're focused on breaking down barriers to care.

Nearly 40% of people living with #HIV reported starting treatment more than 30 days post-diagnosis. To help bridge this gap, it’s imperative to heighten awareness of the benefits of rapid treatment initiation. Learn more about our research at #IAS2025. gilead.inc/4nVbbsU

At Gilead, our focus is on turning scientific innovation into real-world impact. Our recent agreement with The @GlobalFund will help expand access to our #HIV prevention medicine once approved in high-incidence, resource-limited countries. #IAS2025

Inclusion in #HIV research leads to better, more equitable outcomes. Yvette Raphael and Moupali Das share how they helped shape Gilead’s prevention trials by prioritizing the voices of young women and adolescent girls. #IAS2025

The results of our new global survey gather insights from people living with HIV – a diverse representation of multiple historically underrepresented communities. This spotlights our commitment to putting people at the center. gilead.inc/3TC9DpY #IAS2025

We’re proud to bring our people-first mission to #IAS2025. We’re driving innovation to help end the #HIV epidemic for everyone, everywhere.

#GileadNews: At #IAS2025, we’re sharing new data on our long-acting HIV prevention medication, with new safety, efficacy and preference data across a broad range of populations, including pregnant and lactating women and young people. Read more: gilead.inc/4kzk5cV

#GileadNews: The @WHO has released new guidelines on our long-acting #HIV prevention medication, as well as updated HIV testing protocols for long-acting HIV medications. Read more: gilead.inc/40MiDMX

We’re committed to meeting the needs of people most affected by #HIV. Next week, we’ll be at #IAS2025, highlighting the intentional inclusion of women in our HIV prevention trial program. Learn more about this work and about our UK Women & HIV campaign: gilead.inc/40AL4h9

#GileadNews: Today, we announced an agreement with @GlobalFund to supply our long-acting #HIV prevention medication for up to two million people over three years in low- and lower-middle-income countries upon approval, at no profit to us. gilead.inc/44R1fsR

As our Month of Service continued, Gilead employees sorted, prepared and distributed food at the @ACCFB, supporting its mission to end hunger in the county. We're proud to partner with organizations like this to continue making a positive impact in the communities we serve.

We proudly joined the San Francisco Pride Parade last weekend, standing with the LGBTQ+ community and living our values of inclusion and respect. We showed up, we marched, we celebrated — and we’ll keep the spirit alive all year long. #GileadLife

This week in Cork, Ireland, we celebrated Gilead's newest facility – a 56,000-square-foot, LEED Gold certified warehouse that expands our global manufacturing network. Our infrastructure is growing with intention, expanding our capacity to meet the evolving needs of patients.

Proud to be named a leader in TIME100’s Most Influential Companies of 2025 — a recognition of our global work. From advancing innovative medicines to expanding access to our therapies, we’re committed to creating a healthier world for all. gilead.inc/3Gh40u7 #GileadLife

Welcomed by @aids_memorial's CEO John Cunningham, Gilead employees rolled up their sleeves and got to work in San Francisco. The volunteer effort was part of our Month of Service, and it reflects our enduring commitment to communities affected by #HIV and AIDS.